Analysts took action on health care stocks on Tuesday.
JPMorgan commenced coverage of BeiGene Ltd. (BGNE, Financial) with an overweight rating. The analyst established a price target of $174 per share, which represents 38.3% upside from the share price of $125.8 at market close on Tuesday.
The share price has increased 46% over the 52 weeks of trading through Nov. 20. It is trading below the 50-, 100- and 200-day simple moving average lines.
The 52-week range is $77.54 to $220.1 per share. The stock has a market capitalization of $7.15 billion, a price-book ratio of 3.77 versus an industry median of 4.1 and a price-sales ratio of 42.41.
BeiGene develops molecularly-targeted and immuno-oncology drugs for the treatment of several forms of cancer.
The stock's recommendation rating is now 1.6 out of 5. Analysts predict a loss of $9.91 per share for fiscal 2018 and a loss of $10.36 per share for fiscal 2019.
The company does not pay a dividend.
GuruFocus assigned BeiGene a financial strength rating of 7 out of 10 and a profitability and growth rating of 3 out of 10.
Brookline Capital Markets started covering development-stage oncology pharmaceutical company Celsion Corp. (CLSN, Financial), assigning a buy rating. The analyst set a price target of $9 per share, reflecting 400% upside from the closing price of $1.8 on Tuesday.
The stock has fallen 41% over the last 52 weeks. The current share price is below the 200-, 100- and 50-day simple moving average lines.
The stock has a market capitalization of $34.5 million. The 52-week range is $1.81 to $3.48 per share. The price-book ratio is 2.19 versus an industry median of 4.1 and the price-sales ratio is 65.72.
Celsion is developing and commercializing directed chemotherapy, RNA-based therapy and DNA-mediated immunotherapy products, which are used to treat several forms of cancer.
The stock has an average target price of $9 per share and a recommendation rating of 1 out of 5.
The company is not paying dividends.
Analysts predict a loss of $1.46 per share for fiscal 2018.
GuruFocus assigned Celsion a financial strength rating of 3 out of 10 and a profitability and growth rating of 3 out of 10.
Brookline Capital Markets has started covering shares of the clinical-stage biopharmaceutical company Cellectar Biosciences Inc. (CLRB, Financial) with a buy rating. The analyst established a price target of $10 per share, which represents a 376.2% upside from the share price of $2.1 at market close on Tuesday.
The stock has fallen 85% for the 52 weeks through Nov. 20. It is trading below the 100- and 200-day simple moving average lines and is almost on par with the 50-day line.
The 52-week range is $2.03 to $15.9 per share. The stock has a market capitalization of $10.23 million and a price-book ratio of 0.61 versus an industry median of 4.1.
Cellectar Biosciences develops drugs to treat a broad range of cancers.
The recommendation rating is 1 out of 5 and the average target price is $8.2 per share.
The company does not have a dividend.
Analysts predict no earnings for fiscal 2018 and a loss of $3.78 per share for fiscal 2019.
GuruFocus assigns Cellectar Biosciences a financial strength rating of 4 out of 10 and a profitability and growth rating of 3 out of 10.
Disclosure: I have no positions in any securities mentioned in this article.
Read more here:
